乳腺癌内科治疗新进展—— 胡夕春.pptVIP

下载本文档

7
0
约1.73万字
约 46页
2017-12-16 发布于浙江
举报
版权申诉

乳腺癌内科治疗新进展—— 胡夕春.ppt

1、本文档共46页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

乳腺癌内科治疗新进展—— 胡夕春

乳腺癌内科治疗新进展胡夕春新药新方案新理念新药不良反应及处理 1.1白蛋白结合紫杉醇 (ABX) 1.2 EFECT: Evaluation of Treatment Options Following AI Failure EFECT: Similar TTP in Patients Treated With Fulvestrant or Exemestane EFECT: Patient Response and Study Conclusions Median duration of response to treatment with fulvestrant vs exemestane: 13.5 vs 9.8 months, respectively Fulvestrant as effective and safe as exemestane in women with hormone receptor–positive breast cancer who have progressed on treatment with a nonsteroidal AI 1.3 Ixabepilone+Capecitabine vs Capecitabine Ixabepilone+Capecitabine vs Capecitabine Ixabepilone+Capecitabine vs Capecitabine 新药新方案新理念新药不良反应及处理 2.1 Lapatinib oral tyrosine kinase inhibitor of ErbB1 and ErbB2 Blocks signaling through EGFR and HER2 homodimers and heterodimers May also prevent signaling between ErbB1/ErbB2 and other ErbB family members Treatment Efficacy: Lapatinib Vs Lapatinib + Trastuzumab Progression-Free Survival: L Vs L+T EGF100151: Lapatinib + Capecitabine in Advanced Breast Cancer EGF100151: Lapatinib + Capecitabine in Advanced Breast Cancer (cont’d) Addition of lapatinib to capecitabine in women with treatment-refractory, advanced metastatic breast cancer associated with Longer time to progression 36.9 vs 19.7 wks (P = .00016) Longer progression-free survival 36.9 vs 17.9 wks (P = .000045) Fewer progressions or deaths 38% vs 48% Response (independent review) Overall: 22.5% vs 14.3% (P = .113) Phase III trial of Avastin plus docetaxel in first-line MBC (AVADO) Recruitment commenced March 2006 and completed in March 2007 Primary endpoint: PFS secondary endpoints: ORR, OS, safety, QoL Trial met primary endpoint; data will be presented mid-2008 Bevacizumab ± Paclitaxel for Locally Recurrent or Metastatic Disease Eastern Cooperative Oncology Group (ECOG) 2100 trial First planned interim analysis of randomized, first-line, phase 3 trial Bevacizumab ± Paclitaxel for Locally Recurrent or Metastatic Disease PFS significantly longer with combinat